LEPRA

LEPRA
28 MiddleboroughColchesterEssexCO1 1TG
Tel: 01206 216700
Fax: 01206 762151
Web: www.lepra.org.uk

Since 1924, LEPRA has been caring for and curing people of leprosy with the aim of eradicating this disease. The development of a simple and cheap treatment called MDT in 1982(multidrug therapy) now makes this objective possible. Early identification and treatment is essential in order to prevent patients from becoming permanently disfigured or disabled. LEPRA works in Angola, Bangladesh, Brazil, Guatemala, India, Nepal, Malawi, Madagascar and Mozambique. Other project activities apart from treatment include the following:

Provision of support to patient groups
Prevention of disability activities
Social and economic rehabilitation
Capacity building

LEPRA is a small organisation of nearly 70 UK and over 400 local overseas staff working on its own direct projects and supporting some government and NGO leprosy control programmes throughout the world. Although LEPRA's prime objective is the eradication of leprosy, it is also concerned about the impact of allied diseases such as TB, HIV/AIDS and malaria. With over three million deaths annually, TB is the largest killer amongst these. Where appropriate, therefore, TB control is being added to existing programmes.LEPRA also funds medical research aimed at improving the quality and effectiveness of treatment and finding new methods of combating the effects of the disease. LEPRA has no political or religious affiliations and the vast majority of funding is through public donations. This is for overseas projects and not projects operated in the United Kingdom.

Leprosy Today

Today, the diagnosis and treatment of leprosy is easy and most endemic countries are striving to fully integrate leprosy services into existing general health services.This is especially important for those under-served and marginalised communities most at risk from leprosy, often the poorest of the poor.

Access to information, diagnosis and treatment with multidrug therapy (MDT) remain key elements in the strategy to eliminate the disease as a public health problem, defined as reaching a prevalence of less than 1 leprosy case per 10,000 population. MDT treatment has been made available by WHO free of charge to all patients worldwide since 1995, and provides a simple yet highly effective cure for all types of leprosy.

According to official reports received during 2008 from 118 countries and territories, the global registered prevalence of leprosy at the beginning of 2008 stood at 212,802 cases, while the number of new cases detected during 2007 was 254,525 (excluding the small number of cases in Europe). The number of new cases detected globally has fallen by 11,100 cases (a 4% decrease) during 2007 compared with 2006.

Most previously highly endemic countries have now reached elimination (defined as a registered prevalence rate of <1 case/10 000 population). During 2007, both the Democratic Republic of the Congo and Mozambique reached this important stage. Those few countries that remain are very close to eliminating the disease. However, pockets of high endemicity still remain in some areas of Angola, Brazil, Central African Republic, Democratic Republic of Congo, India, Madagascar, Mozambique, Nepal, and the United Republic of Tanzania. These countries remain highly committed to eliminating the disease, and continue to intensify their leprosy control activities.

Information campaigns about leprosy in high risk areas are crucial so that patients and their families, who were historically ostracized from their communities, are encouraged to come forward and receive treatment. The most effective way of preventing disabilities in leprosy, as well as preventing further transmission of the disease, lies in early diagnosis and treatment with MDT.